4,817 reports of this reaction
6.1% of all FLUTICASONE PROPIONATE AND SALMETEROL reports
#2 most reported adverse reaction
DRUG INEFFECTIVE is the #2 most commonly reported adverse reaction for FLUTICASONE PROPIONATE AND SALMETEROL, manufactured by GlaxoSmithKline LLC. There are 4,817 FDA adverse event reports linking FLUTICASONE PROPIONATE AND SALMETEROL to DRUG INEFFECTIVE. This represents approximately 6.1% of all 78,422 adverse event reports for this drug.
Patients taking FLUTICASONE PROPIONATE AND SALMETEROL who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is moderately reported among FLUTICASONE PROPIONATE AND SALMETEROL users, representing a notable but not dominant share of adverse events.
In addition to drug ineffective, the following adverse reactions have been reported for FLUTICASONE PROPIONATE AND SALMETEROL:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 4,817 FDA reports for FLUTICASONE PROPIONATE AND SALMETEROL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 6.1% of all adverse event reports for FLUTICASONE PROPIONATE AND SALMETEROL, making it one of the most commonly reported side effect.
If you experience drug ineffective while taking FLUTICASONE PROPIONATE AND SALMETEROL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.